These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30131447)

  • 1. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion.
    Wang R; Bhattacharya R; Ye X; Fan F; Boulbes DR; Ellis LM
    Mol Cancer Res; 2019 Jan; 17(1):20-29. PubMed ID: 30131447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cells activate the cancer stem cell-associated NANOGP8 pathway in colorectal cancer cells in a paracrine fashion.
    Wang R; Bhattacharya R; Ye X; Fan F; Boulbes DR; Xia L; Ellis LM
    Mol Oncol; 2017 Aug; 11(8):1023-1034. PubMed ID: 28453235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Endothelium Promotes HER3-Mediated Cell Survival in Colorectal Cancer with Wild-Type and Mutant KRAS.
    Rathore M; Zhang W; Wright M; Bhattacharya R; Fan F; Vaziri-Gohar A; Winter J; Wang Z; Markowitz SD; Willis J; Ellis LM; Wang R
    Mol Cancer Res; 2022 Jun; 20(6):996-1008. PubMed ID: 35276002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma.
    Rathore M; Zhang W; Wright M; Zarei M; Vaziri-Gohar A; Hajihassani O; Abbas A; Feng H; Brody J; Markowitz SD; Winter J; Wang R
    J Cancer Sci Clin Ther; 2022; 6(4):431-445. PubMed ID: 36644317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.
    De Boeck A; Pauwels P; Hensen K; Rummens JL; Westbroek W; Hendrix A; Maynard D; Denys H; Lambein K; Braems G; Gespach C; Bracke M; De Wever O
    Gut; 2013 Apr; 62(4):550-60. PubMed ID: 22535374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.
    Bose D; Zimmerman LJ; Pierobon M; Petricoin E; Tozzi F; Parikh A; Fan F; Dallas N; Xia L; Gaur P; Samuel S; Liebler DC; Ellis LM
    Br J Cancer; 2011 Nov; 105(11):1759-67. PubMed ID: 22045189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COPS5 and LASP1 synergistically interact to downregulate 14-3-3σ expression and promote colorectal cancer progression via activating PI3K/AKT pathway.
    Zhou R; Shao Z; Liu J; Zhan W; Gao Q; Pan Z; Wu L; Xu L; Ding Y; Zhao L
    Int J Cancer; 2018 May; 142(9):1853-1864. PubMed ID: 29226323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
    Koganemaru S; Kuboki Y; Koga Y; Kojima T; Yamauchi M; Maeda N; Kagari T; Hirotani K; Yasunaga M; Matsumura Y; Doi T
    Mol Cancer Ther; 2019 Nov; 18(11):2043-2050. PubMed ID: 31395690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
    Chin CC; Li JM; Lee KF; Huang YC; Wang KC; Lai HC; Cheng CC; Kuo YH; Shi CS
    J Cell Physiol; 2016 Feb; 231(2):459-72. PubMed ID: 26189563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast activation protein-α in tumor cells promotes colorectal cancer angiogenesis via the Akt and ERK signaling pathways.
    Cao F; Wang S; Wang H; Tang W
    Mol Med Rep; 2018 Feb; 17(2):2593-2599. PubMed ID: 29207091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.